Articles tagged with Colorectal Cancer
A new fecal SDC2 methylation assay, combined with the Asia-Pacific Colorectal Screening Scoring (APCS), demonstrates superior performance in detecting advanced adenomas and stratifying risk. The test's high specificity makes it a valuable tool for prioritizing colonoscopy.
A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.
Researchers developed mRNA-encoded nanobodies to combat colorectal cancer, offering new hope for patients resistant to conventional immunotherapies. The treatment demonstrated superior efficacy against sporadic and colitis-associated colorectal cancer.
Researchers found that both screening methods lead to more cases of early-stage cancer being detected, especially in the first two years. The study suggests that screening may have a preventive effect by removing precursors to cancer.
Researchers identify UBR5 as a critical tumor suppressor that modulates Snail's stability, facilitating metastasis. UBR5 maintains epithelial phenotype by targeting Snail for degradation, while its deficiency promotes Snail stabilization and metastatic cascade.
Researchers identify PAK1 as a key player in colorectal cancer progression through its ability to stabilize mRNA of oncogenic factors. Targeting PAK1 inhibits proliferation, migration, and invasion, promoting the degradation of these transcripts and sensitizing tumors to standard-of-care treatments.
Researchers from the University of Southern Denmark have identified a new virus in a common gut bacterium that appears more frequently in patients with colorectal cancer. The study demonstrates a statistical association between the virus and colorectal cancer, but its role is still unclear.
A study by University of Texas at Dallas bioengineers found that both cancerous and noncancerous colon tissue from young patients with colorectal cancer was mechanically stiffer than in older patients. This stiffness may promote the development of early-onset colorectal cancer, a condition rising over the past 30 years.
A new study uses AI to predict which ulcerative colitis patients with low-grade dysplasia are at high risk of developing colorectal cancer. The model integrates risk factors from narrative clinical notes, enabling more accurate and timely surveillance and potentially reducing treatment delays.
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
In a mouse study, researchers successfully used RNA micelles to shrink metastasized tumors in lungs by delivering chemotherapy drugs and an RNA molecule that blocks cancer survival. The treatment significantly reduced tumor growth and improved outcomes for mice with colorectal cancer lung metastasis.
Researchers found OXCT1 to be a key regulator of colorectal cancer liver metastasis, with low expression linked to increased metastasis. OXCT1 suppression promotes oncogenic signaling through the CDK8/beta-catenin complex, highlighting its potential as a novel therapeutic target and prognostic biomarker.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
Research reveals that higher lifetime alcohol consumption is associated with a higher risk of colorectal cancer, especially for rectal cancer. Quitting drinking can lower a person’s risk, according to the findings published in CANCER, a peer-reviewed journal.
Researchers found that TL1A, a key immune signaling protein, stimulates the growth of new white blood cells in the bone marrow, which then promote tumor formation in the gut. The study suggests that blocking TL1A activity could be an effective strategy to treat IBD and prevent associated colorectal tumors.
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
Researchers found that NOUS-209 safely stimulated the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome, providing early evidence of its potential to intercept cancer before it develops. The vaccine-induced T cells were able to kill tumor cells and showed signs of long-lasting immune memory.
Researchers at Umea University have discovered a bacterial toxin, MakA, that can inhibit colorectal cancer growth without causing damage to the body. The substance changes the immune microenvironment in tumors and boosts the immune system's ability to fight cancer.
A deep learning model trained on stage II colorectal cancer whole slide images accurately identified features linked to recurrence risk. The study found the model surpassed clinical prognostic parameters in predicting patient outcomes.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
Research from Radboud University Medical Center and colleagues demonstrates the value of targeted tumor analysis of DNA in colorectal polyps. This study provides valuable insights into genetic predispositions, including APC mutational mosaicism and BRAF gene mutations.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Researchers identified specific microbial patterns associated with tumor location, genetic features, and patient outcomes. A new Microbial Risk Score (MRS) offers a practical way to translate complex microbiome data into prognostic insight.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A community awareness campaign in Nigeria increased awareness of colorectal cancer symptoms and risk factors, leading to earlier detection of the disease. The program also identified precancerous polyps and detected colorectal cancer at curable stages.
Researchers at Kyoto University identified five molecular subtypes of colorectal cancer stem cells and developed a practical prognostic indicator, the general colorectal cancer signature (GCS), to predict patient outcomes. The GCS was validated with a novel orthotopic xenograft mouse model and showed promising clinical significance.
Researchers used machine learning to combine clinical data with biological markers, achieving 89.58% accuracy in predicting patient survival. The study identified key markers such as E2F8, WDR77, and hsa-miR-495-3p, which were associated with tumor growth and cancer development.
BGI Genomics convened its 2025 European Partnership & Networking Summit in Budapest, fostering innovation, collaboration, and growth. The event introduced its comprehensive NGS solution, Gensiro, integrating AI and automation to streamline laboratory workflows.
Researchers from MSK discovered that two distinct subtypes of regulatory T cells play opposing roles in colorectal cancer, with one restraining tumor growth and the other fueling it. The study suggests that selective approaches to targeting these cells could improve immunotherapy treatment for most patients with colorectal cancer.
The grant aims to increase individual screenings and change how health systems embed evidence-based screening practices into everyday operations. PA-CARES will work with trusted organizations in 28 counties with the lowest screening rates to implement effective screening options and facilitate timely linkage to care.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
Researchers found that sudden cardiac death (SCD) among colorectal cancer patients decreased overall, but disparities remained based on age, sex, and geographic location. The study highlights the need for tailored heart monitoring and care strategies for cancer patients, particularly in underserved groups.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
This study reveals significant viral-host interactions in colorectal polyps, identifying specific viruses associated with oncogenic and tumor-suppressive transcriptomic profiles. The findings suggest that viral activity contributes to early neoplastic transformation, challenging the traditional view of viruses as mere bystanders.
A new study reveals that social determinants of health have a significant impact on rural–urban differences in colorectal cancer mortality rates. The research found that low socioeconomic status, household characteristics, and racial/ethnic minority status were key drivers of these disparities.
A new review connects gut microbiome imbalances to obesity, metabolic syndrome, and colorectal cancer, highlighting the potential for diet and microbiome-based treatments. The study also explores racial and socioeconomic disparities in microbiome-related diseases, emphasizing the need for inclusive prevention strategies.
Researchers at MD Anderson have discovered bacterial genetic and cellular elements within brain tumor cells, potentially influencing tumor behavior. Inflammation may also drive the earliest stages of lung cancer, with targeting proinflammatory pathways emerging as a potential early intervention approach
Researchers found that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the USPSTF lowered the recommended screening age to 45. Despite investigating unmet social needs, no significant differences were found in testing uptake for this early midlife cohort.
A new bio-heterojunction platform integrates electrogenic bacteria with piezoelectric nanoparticles to eradicate colorectal tumors and restore the gut microbiome. The platform induces two distinct forms of tumor cell death, apoptosis and pyroptosis, and effectively remolds the tumor microenvironment.
A study of nearly 30,000 female nurses found that consuming more ultra-processed foods was associated with a 45% higher risk of developing adenomas, precursors to early-onset colorectal cancer. The study's findings support the importance of reducing ultra-processed food intake as a strategy to mitigate the rising burden of early-onset ...
Researchers developed a new DNA analysis technique to study old genetic samples, shedding light on disease evolution and changes in biology over time. The approach has potential for unlocking the root causes underlying shifting landscapes of modern diseases.
A study found that higher consumption of ultraprocessed foods is associated with an increased risk of developing early-onset colorectal cancer precursors. The research highlights the importance of improving dietary quality to mitigate the rising burden of early-onset colorectal cancer.
A new study from Mass General Brigham researchers identified distinct T-cell infiltration patterns in colorectal cancer precursor lesions and cancer tissues. The findings suggest that understanding these patterns could help detect CRC earlier by predicting risk and develop therapeutic approaches.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Research highlights the importance of mitochondria-endoplasmic reticulum cross-talk in colorectal cancer, regulating Ca2+ homeostasis and lipid metabolism. Novel therapeutic strategies targeting this crosstalk may suppress CRC progression and improve patient outcomes.
A study reveals how colorectal tumors use TGF-β to prevent immune cells from reaching and attacking the tumor. The researchers suggest strategies to improve immunotherapy efficacy by blocking this dual barrier and identifying new therapeutic targets.
A cohort study finds nearly 10-fold increase in facility-based screening among 45-49 year olds after USPSTF guideline changes. This rapid growth highlights early implementation by practitioners and patients, far exceeding growth among those ages 50 to 75.
Colorectal cancer screening modities shifted among privately insured individuals after COVID-19, with decreased colonoscopy and fecal tests, increased stool DNA tests. Differences found by sex, socioeconomic status, and metropolitan area residence.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
The study reveals geographic clusters of high and low screening for breast, cervical, and colorectal cancers in the US Northeast and Southwest. Future studies could examine county-level healthcare access to optimize cancer screening practices.
Researchers at UC Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery. The model shows promising results in detecting resistance to chemotherapy drugs, making it a potential alternative to traditional animal testing.
Researchers at UT Austin have developed a new cancer treatment that uses LED light and SnOx nanoflakes to precisely target cancer cells without harming healthy ones. The treatment achieved remarkable effectiveness in neutralizing colorectal and skin cancer cells, with up to 92% kill rate in just 30 minutes of exposure.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers found microplastic exposure changes the human gut microbiome, with some shifts resembling patterns linked to diseases. Microplastic-induced changes in microbial composition may serve as a bacterial stress response, potentially affecting overall well-being.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
A California court has ruled that processed meat, classified as a carcinogen by the World Health Organization, should not be included on the state's Proposition 65 list. This decision endangers public health and increases colorectal cancer risk, particularly among younger people.
The University of Cincinnati Cancer Center is conducting a study on combining KRAS inhibitors with HER3 targeted agents to treat colorectal cancers. The goal is to extend patient lives and reduce toxic treatments. Researchers hope to develop new, less-toxic options for patients whose cancer has spread.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.